Latest Healthcare News

Ansell Limited has updated its FY26 interim dividend details, confirming a USD 0.266 per share payout and setting the Dividend Reinvestment Plan price at USD 22.24 per share. The dividend will be paid in US dollars with an Australian dollar equivalent of AUD 0.3768 per share.

dorsaVi has formed a world-class Technical Advisory Board to accelerate its pioneering ‘Intelligence at the Ultra Edge’ strategy, integrating advanced memory and neuromorphic computing into robotics and healthcare devices.

Mach7 Technologies has completed its on-market share buy-back, acquiring over six million shares at an average price well below the initial $5 million cap. The move signals a cautious but confident approach to capital management amid evolving market conditions.

Unith Ltd has launched its Streaming Avatars technology, delivering a dramatic latency reduction and validated by strong customer feedback, setting a new standard for real-time digital human interactions.

Rhythm Biosciences has inked a pivotal distribution agreement with UK-based Digistain Limited to introduce its geneType™ genetic test portfolio in Southeast Asia, starting with the Philippines. This marks Rhythm’s first commercial foothold in the region, setting the stage for broader expansion.

Control Bionics has secured a key regulatory milestone with its NeuroNode device now eligible for reimbursement under Germany’s statutory health insurance, paving the way for expanded European distribution.

Osteopore Limited has landed a two-year distribution deal for an innovative autologous dentin graft technology in Singapore, setting the stage for expansion across ASEAN and the wider Asia-Pacific dental market.

Chimeric Therapeutics has secured a $1.785 million advance against its anticipated FY26 Research and Development Tax Incentive to bolster its clinical trial pipeline and working capital.

Epsilon Healthcare Limited has reported a robust recovery in 2025, with revenue climbing 68% to $9.39 million and net losses shrinking by 63%, driven by growth in contract manufacturing and a new pharmacy division.

Botanix Pharmaceuticals reports a surge in Sofdra sales driving revenue to $16.5 million, yet the company records a $33.2 million loss amid expanded marketing and operational costs. A $45 million capital raise aims to support growth and supply chain improvements.

IMEXHS Limited delivered FY25 results at the top end of guidance, reporting a 10% revenue increase and a tripling of underlying EBITDA. The company’s software and radiology services both showed solid growth, setting the stage for an optimistic FY26 outlook.

Memphasys Limited has advanced its Felix™ System commercial rollout with key regulatory approvals and new international contracts, while trimming operating costs and narrowing losses in the first half of FY2026.